The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain
Abstract
Objective: To evaluate pituitary function, sexual function and quality of life (QoL) in patients on oral or transdermal opioids. Design and methods: Cross-sectional study comparing pituitary function, QoL and sexual function in people on long-term opioid therapy (n = 40) vs an age- and sex-matched control group (n = 25). Baseline pituitary function was assessed on blood samples collected prior to 0900 h. Further testing with corticotropin (250 µg IV) and metyrapone (30 mg/kg) stimulation tests was undertaken on participants with serum cortisol <250 nmol/L. Validated questionnaires completed to assess QoL, fatigue and sexual function. Results: Secondary adrenal insufficiency (SAI) was identified on the basis of a failed stimulation test in 22.5% of opioid users vs no controls (P = 0.01). Opioid users with SAI had a higher median morphine-equivalent daily dose (MEDD),P = 0.037 – 50% with MEDD >200 mg and 0% with MEDD <60 mg had SAI. Among male participants, testosterone was inversely associated with BMI (P = 0.001) but not opioid use. A non-significant trend to low testosterone <8 nmol/L in male opioid users (11/24 opioid users vs 2/14 control,P = 0.08) suggests a small subgroup with opioid-induced androgen deficiency. Opioid users had greater fatigue, reduced quality of life in all subsections of the SF-36 and impaired sexual function in both males and females (all scores P < 0.001 compared to controls). Conclusion: Long-term opioid therapy was associated with dose-related SAI in over 20% of chronic pain patients and is associated with poor quality of life, fatigue and sexual dysfunction. Obesity confounds the interpretation of opioid-induced male androgen deficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both opioid use and the pain syndromes may result in a broad spectrum of symptoms and signs that impact health-related quality of life, including physical function, sexual function, mental health, and fatigue hindering the interpretation of the relationship between health-related quality of life and hormonal data (116, 124).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [116]
In the citing paper
“In a study assessing the effects of long-term oral or transdermal opioids in patients with noncancer pain, an overall rate of secondary adrenal insufficiency of 22.5% (9 out of 40) was reported (defined as failing either an ACTH1-24 stimulation test or an overnight metyrapone test) (116).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [116]
In the citing paper
“No patient on an MME dose of below 60 mg per day showed a suboptimal response (116).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [116]
In the citing paper
“In a study of 40 patients on oral or transdermal opioids for chronic pain (for more than 6 months at an MME dose ≥25 mg) and 25 controls not taking opioids, the opioid users had lower IGF-I (138 mcg/L [99-161] vs 168 mcg/L [138-214]; P = .004),although none of them had levels below the lower limit of the reference ranges (116).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [116]
In the citing paper
“Variable results have also been described for the peripheral thyroid hormones; T4 levels were unaffected (74, 118, 136, 159, 160) or decreased (116, 160-162) and T3 levels were increased (74, 159) or unaffected (160) or decreased (161).”
From Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement (2024) · cites this paper as [116]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Rosen, C. B. (2000) · Journal of Sex & Marital Therapy · doi:10.1080/009262300278597 · Cited by 6,593
Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849
The rand 36‐item health survey 1.0
Hays, R. D., Sherbourne, C. D., & Mazel, R. M. (1993) · Health Economics · doi:10.1002/hec.4730020305 · Cited by 2,884
Opioid Complications and Side Effects
Benyamin, R. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/s105 · Cited by 2,245
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
Self-citationHannibal, K. E., & Bishop, M. D. (2014) · Physical Therapy · doi:10.2522/ptj.20130597 · Cited by 729
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
Endocrine consequences of long-term intrathecal administration of opioids
Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J.-P., Opsomer, F., Adriaensen, H., Verlooy, J., Van Havenbergh, T., Smet, M., & Van Acker, K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6615 · Cited by 491
Hypogonadism in men consuming sustained-action oral opioids
Daniell, H. W. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.126790 · Cited by 401
Research works printed but not linked: 42
- 2010, Measuring fatigue in clinical and community settings, Journal of Psychosomatic Research, 69, 17, 10.1016/j.jpsychores.2009.10.007 · DOI · Paper page
- 2000, Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing, Medical Journal of Australia, 172, 220, 10.5694/j.1326-5377.2000.tb123913.x · DOI
- 2016, Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline, Journal of Clinical Endocrinology and Metabolism, 101, 364, 10.1210/jc.2015-1710 · DOI · Paper page
- 2015, Opioid analgesic prescribing in Australia: a focus on gender and age, Pharmacoepidemiology and Drug Safety, 24, 628, 10.1002/pds.3767 · DOI
- 2009, Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women, Experimental and Clinical Endocrinology and Diabetes, 117, 38
- 2006, The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study, Cancer, 107, 2949, 10.1002/cncr.22339 · DOI · Paper page
- 2015, Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial, Pain, 156, 280, 10.1097/01.j.pain.0000460308.86819.aa · DOI · Paper page
- 1995, Elevated basal adrenocorticotropin and evidence for increased central opioid tone in highly trained male athletes, Journal of Clinical Endocrinology and Metabolism, 80, 244
- 2007, Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatment, Clinical Endocrinology, 66, 604, 10.1111/j.1365-2265.2007.02779.x · DOI · Paper page
- 2005, Chronic fentanyl application induces adrenocortical insufficiency, Journal of Internal Medicine, 257, 478, 10.1111/j.1365-2796.2005.01483.x · DOI · Paper page
- Opioid, complications side effects, Pain Physician, 200811
- 2000, Comparison of one week 0900 h serum cortisol, low and standard dose synacthen tests with a 4 to 6 week insulin hypoglycaemia test after pituitary surgery in assessing HPA axis, Clinical Endocrinology, 53, 431, 10.1046/j.1365-2265.2000.01106.x · DOI
- 2017, Treatment of hypogonadism: current and future therapies, F1000 Research, 6, 68, 10.12688/f1000research.10102.1 · DOI · Paper page
- 2008, Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain, Journal of Pain, 9, 28, 10.1016/j.jpain.2007.08.005 · DOI · Paper page
- 2018, Characterization of the serum and salivary cortisol response to the intravenous 250 microg ACTH1-24 stimulation test, Endocrine, 59, 520, 10.1007/s12020-017-1505-0 · DOI
- 1997, The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction, Urology, 49, 822, 10.1016/S0090-4295(97)00238-0 · DOI · Paper page
- 2010, The effects of opioids and opioid analogs on animal and human endocrine systems, Endocrine Reviews, 31, 98, 10.1210/er.2009-0009 · DOI · Paper page
- 1985, Effect of naloxone on the hormone response to CRF in normal man, Endocrine Research, 11, 39, 10.3109/07435808509035423 · DOI
- 1997, Which patients benefit from provocative adrenal testing after transsphenoidal pituitary surgery?, Clinical Endocrinology, 46, 21, 10.1046/j.1365-2265.1997.d01-1748.x · DOI
- 1993, Differential changes in serum concentrations of androgens and estrogens (in relation with cortisol) in postmenopausal women with acute illness, Journal of Clinical Endocrinology and Metabolism, 76, 1542
- 2014, Chronic stress, cortisol dysfunction, and pain: a psychoneuroendocrine rationale for stress management in pain rehabilitation, Physical Therapy, 94, 1816, 10.2522/ptj.20130597 · DOI · Paper page
- 2015, Low-dose hydrocortisone replacement improves wellbeing and pain tolerance in chronic pain patients with opioid-induced hypocortisolemic responses. A pilot randomized, placebo-controlled trial, Psychoneuroendocrinology, 56, 157, 10.1016/j.psyneuen.2015.03.015 · DOI · Paper page
- 2009, Secondary adrenal insufficiency due to opiate therapy – another differential diagnosis worth consideration, Experimental and Clinical Endocrinology and Diabetes, 117, 649, 10.1055/s-0029-1202851 · DOI · Paper page
- 2011, Opioid-induced biochemical alterations of the neuroendocrine axis, Expert Review of Endocrinology and Metabolism, 6, 705, 10.1586/eem.11.55 · DOI
- 2017, New diagnostic criteria for subclinical hypercortisolism using postsurgical hypocortisolism: the Co-work of Adrenal Research study, Clinical Endocrinology, 86, 10, 10.1111/cen.13145 · DOI
- 2008, Prospective evaluation of a protocol for reduced glucocorticoid replacement in transsphenoidal pituitary adenomectomy: prophylactic glucocorticoid replacement is seldom necessary, Clinical Endocrinology, 68, 29, 10.1111/j.1365-2265.2007.02995.x · DOI
- 2011, General Health Questionnaire – 28 (GHQ-28), Journal of Physiotherapy, 57, 259, 10.1016/S1836-9553(11)70060-1 · DOI · Paper page
- 1990, Metyrapone effects on β-endorphin, ACTH and cortisol levels after chronic opiate receptor stimulation in man, Neuropeptides, 15, 129, 10.1016/0143-4179(90)90143-M · DOI
- 2016, Adrenal insufficiency in patients on long-term opioid analgesia, Clinical Endocrinology, 85, 831, 10.1111/cen.13125 · DOI · Paper page
- 2010, Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment, Clinical Journal of Pain, 26, 374, 10.1097/AJP.0b013e3181d1059d · DOI · Paper page
- 2004, Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids, Cancer, 100, 851, 10.1002/cncr.20028 · DOI · Paper page
- 2011, Tramadol-induced adrenal insufficiency, European Journal of Clinical Pharmacology, 67, 865, 10.1007/s00228-011-0992-9 · DOI
- 2000, The low dose ACTH stimulation test is less sensitive than the overnight metyrapone test for the diagnosis of secondary hypoadrenalism, Clinical Endocrinology, 53, 221, 10.1046/j.1365-2265.2000.01057.x · DOI · Paper page
- 1986, Interference of endogenous B endorphin with opiate binding in the anterior pituitary, Neuropeptides, 8, 377, 10.1016/0143-4179(86)90009-0 · DOI
- 2017, The role of testosterone supplemental therapy in opioid-induced hypogonadism: a retrospective pilot analysis, American Journal of Men’s Health, 11, 1208, 10.1177/1557988316672396 · DOI · Paper page
- 2002, Hypogonadism in men consuming sustained-action oral opioids, Journal of Pain, 3, 377, 10.1054/jpai.2002.126790 · DOI · Paper page
- 2006, DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production, Journal of Pain, 7, 901, 10.1016/j.jpain.2006.04.011 · DOI
- 2000, Endocrine consequences of long-term intrathecal administration of opioids, Journal of Clinical Endocrinology and Metabolism, 85, 2215, 10.1210/jcem.85.6.6615 · DOI · Paper page
- 2000, The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function, Journal of Sex and Marital Therapy, 26, 191, 10.1080/009262300278597 · DOI · Paper page
- 2017, Prospective evaluation of a week one overnight metyrapone test with subsequent dynamic assessments of hypothalamic-pituitary-adrenal axis function after pituitary surgery, Clinical Endocrinology, 87, 35, 10.1111/cen.13334 · DOI
- 1987, Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain, Journal of Neuroscience, 7, 2445
- 1993, The RAND 36-Item Health Survey 1.0, Health Economics, 2, 217, 10.1002/hec.4730020305 · DOI · Paper page
Cited by
Husebye, E. S., Pearce, S. H., Krone, N. P., & Kämpe, O. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00136-7 · Cited by 378
Hahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Self-citationOpioids and their endocrine effects: a systematic review and meta-analysis
de Vries, F., Bruin, M., Lobatto, D. J., Dekkers, O. M., Schoones, J. W., van Furth, W. R., Pereira, A. M., Karavitaki, N., Biermasz, N. R., & Zamanipoor Najafabadi, A. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz022 · Cited by 139
Opioid-induced endocrinopathies
Fountas, A., Van Uum, S., & Karavitaki, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30254-2 · Cited by 77
KotliÅ„ska-Lemieszek, A., & Zylicz, Z. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s342409 · Cited by 74
“resulting in decreased adrenocorticotropin (ACTH) release.(3,62,63) Both short-term and long-term use of opioids”
Metadata
- Authors
- Lamprecht, A., Sorbello, J., Jang, C., Torpy, D. J., & Inder, W. J.
- Affiliations
- The University of Queensland (AU)
- Princess Alexandra Hospital (AU)
- Royal Adelaide Hospital (AU)
- Corresponding author
- Inder, Warrick J
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-12
- Volume
- 179
- Issue
- 6
- Pages
- 353-362
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2890361357
- Semantic Scholar
- 2759f18ed9a4fa007d141834bdbd16fba7227247
- Cited by
- 52
- References
- 42
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 6 · 2022: 7 · 2021: 7 · 2020: 8 · 2019: 11 · 2018: 1
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- secondary adrenal insufficiency, pituitary dysfunction, long-term opioid therapy, transdermal opioids, chronic non-cancer pain, quality of life, sexual dysfunction, fatigue, testosterone, androgen deficiency, obesity, morphine equivalent daily dose, cortisol, ACTH stimulation test
- MeSH terms
- Administration, Cutaneous, Administration, Oral, Adrenal Insufficiency, Adult, Aged, Analgesics, Opioid, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Pituitary Gland, Pituitary Hormones, Quality of Life, Sexual Dysfunction, Physiological, Young Adult, Chronic Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain. https://app.cochat.ai/papers/10.1530/eje-18-0530
- The paper
- Lamprecht, A., Sorbello, J., Jang, C., Torpy, D. J., & Inder, W. J. (2018). Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain. European Journal of Endocrinology. https://doi.org/10.1530/eje-18-0530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.